Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | IMM2902 |
Synonyms | |
Therapy Description |
IMM2902 is a bispecific monoclonal antibody trap that binds to CD47 and ERBB2 (HER2) and potentially inhibits tumor growth (Cancer Res (2022) 82 (12_Supplement): 6280). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
IMM2902 | IMM-2902|IMM 2902 | CD47 Antibody 31 HER2 (ERBB2) Antibody 76 | IMM2902 is a bispecific monoclonal antibody trap that binds to CD47 and ERBB2 (HER2) and potentially inhibits tumor growth (Cancer Res (2022) 82 (12_Supplement): 6280). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05076591 | Phase I | IMM2902 | IMM2902, a HER2/SIRPalpha Bispecific mAb-Trap Antibody-receptor Fusion Protein, in Patients With HER2-expressing Advanced Solid Tumors | Suspended | USA | 0 |